醫療包裝市場 - 增長、趨勢、COVID-19 影響和預測（2022-2027 年）

醫療包裝市場預計在預測期內（2022-2027 年）將以 6.4% 的複合年增長率增長。

此外，隨著高科技設備和儀器的部署以提高效率以及對可持續包裝和加工操作的需求，醫療保健行業已從傳統的醫療保健形式發展到目前的先進水平。上升。

主要亮點

• 對環境問題和政府法規的認識不斷提高，正在推動製藥公司轉向可持續的流程。此外，由於醫療器械和藥品供應商的發展，醫療保健包裝市場具有全球擴張空間。
• 醫療器械包裝必須為內容物提供無菌環境，並在打開包裝使用之前保持無菌狀態。隨著醫院、治療設備和診斷中心數量的增加，醫療保健行業繼續增長。由於環境問題的增加和對微生物包裝的需求不斷增長，預計無菌包裝的銷售額將增加。
• 醫療保健公司投資於先進的機器以提高包裝速度和效率。例如，數字技術、物聯網和區塊鏈使公司能夠將家用電器連接到智能設備，以排除故障和報告錯誤、優化運營、深入了解機器數據以及記錄跨供應鏈的數據。
• Amcor PLC 在 2022 年 5 月表示，對可持續包裝的需求包括對藥品包裝公司的監管壓力。藥品包裝在立法對可持續性的關注中呈上升趨勢。如果包裝被認為是不可回收的，企業可能會受到擬議的擴展生產者責任 (EPR) 稅和罰款的約束。某些類型的藥品包裝是不可回收的，可能會受到該法律的影響。
• 此外，自 2022 年 5 月起，根據美國食品藥品監督管理局 (Food & Drug Administration) 的規定，DQSA 的第二章《藥品供應鏈安全法》(DSCSA) 會在某些處方藥進入美國時對其進行識別和跟蹤。為此，它概述了在包裹級別實現可互操作的電子跟蹤的步驟。這將增強 FDA 保護消費者免受假冒、被盜、受污染或其他有害藥品的侵害的能力。這些需求還促使公司開發可持續的包裝解決方案，以改善從藥品供應鏈中檢測和清除潛在有害藥物的能力，從而保護美國消費者。
• 藥品包裝行業也因其產品的脆弱性而面臨許多挑戰。包裝不當會導致開發產品發生化學變化，影響癒合和無效性能。還存在諸如供應鏈中斷、監管問題和假冒商品等挑戰。
• 此外，COVID-19 的傳播對市場產生了一定的負面影響，因為全球工廠已長期關閉，供應鏈已中斷。瓶子、小瓶和安瓿瓶製造商在供應製藥公司時面臨物流挑戰。諸如此類的案例正在製約市場的增長。

主要市場趨勢

泡罩包裝有望顯著增長

• 泡罩包裝是最流行和最方便的劑型之一。醫療保健包裝行業的公司為傳統市場產品提供了一種經濟的替代方案，使醫療保健和製藥公司能夠滿足可持續發展目標和保質期要求。泡罩包裝用於醫療器械和器械，例如導管和皮下注射器。然而，泡罩包裝對於醫療器械包裝的用處不如藥品包裝。
• 新疾病的出現、精明客戶的出現以及以公共衛生保健為重點的 OTC（非處方藥）的增長正在加速泡罩包裝在製藥行業的增長。此外，泡罩包裝越來越受歡迎，以保護藥物免受潮濕。為了應對這些趨勢，Burgopak 和 Ecobliss 等公司正在開發創新的兒童安全泡罩包裝。
• 市場供應商正在採取重要的先行者舉措來應對材料的使用。例如，2021 年 10 月，Astellas開始在其泡罩包裝中使用植物衍生的生物質衍生聚合物作為藥品的初級包裝。這種泡罩包裝含有 50% 的生物質衍生塑料聚乙烯，由甘蔗製成。這是一個綠色包裝，它堅定地堅持追求溫室氣體排放和吸收之間平衡的碳中和概念。
• 此外，Amcoa 於 2021 年 4 月發布了 Custom Trail，這是第一個基於可回收聚乙烯的熱成型泡罩包裝。新包裝預計將於 2022 年下半年上市，並符合高度專業化和受監管的藥品包裝的嚴格標準，同時為高需求的醫療保健包裝類型提供更可持續的替代方案。與其他包裝形式相比，碳足跡高達 70%。
• 此外，醫療保健、營養和製藥行業越來越意識到需要減少需要數年才能降解的塑料的使用，並為供應商提供與平板電腦相同的質量和存儲空間。推出與無塑料泡罩包裝，經久耐用。泡罩包裝設計中固有的許多優點與製藥行業的當前需求是一致的。因此，泡罩包裝已成為行業中增長最快的包裝選擇之一，並將繼續如此。

北美有望主導市場

• 在北美，美國和加拿大是經濟蓬勃發展、人口老齡化、醫療保健提供系統完善、國內生產總值 (GDP) 水平和醫療保險水平較高的國家。然而，由於其作為領先的初級保健地區的地位、強大的醫療保健和生命科學研究活動、醫療保健支出的高度集中以及重磅藥物，美國是醫療保健包裝產品的最大地理市場。
• 根據 IQVIA Inc. 於 2021 年 5 月進行的一項研究，美國的淨醫療保健支出總額將從 2020 年的 3590 億美元增加到 2025 年的 3800 億美元至 4000 億美元，年復合增長率為預計為 0% 至 3%。新品牌的推出預計將繼續創下歷史新高，每年推出 50 至 55 種新的活性成分，到 2025 年花費約 1330 億美元，略高於過去五年。
• 此外，由於從加拿大以外的國家進口大量藥品，美國政府已批准批發商和藥劑師從加拿大進口 FDA 批准的藥品的試點項目。 FDA 已經實施了一條從加拿大進口某些處方藥的合法途徑，以降低某些處方藥對美國消費者的成本，而不會給公共健康和安全帶來新的風險。我來了。這將增加對該國的進口並推動醫療保健包裝市場。
• 公司還專注於擴大業務以獲取更多收入並保持市場競爭力。例如，2022 年 6 月，Guardian Medical USA 最近籌集了超過 200 萬美元的私人資金，專注於骨科醫療器械市場的無菌屏障包裝。有了這筆資金，公司計劃加速產品開發和設施增長，以滿足對使用剛性管材對各種類型和尺寸的骨科植入物和設備進行無菌包裝的日益增長的需求和興趣。
• 同樣，在 2021 年 9 月，Jones Healthcare Group 和 Good Nature Products, Inc. 合作在一個新的創新設施中擴展可持續包裝解決方案。借助這種基於植物的新解決方案，Jones 計劃在大多數北美家庭中簡化包裝設計、消除化學問題並實現易於回收的包裝。這種新的定制泡罩包裝的成分可在加拿大各地的獨立國家連鎖藥店購買。

競爭格局

醫療保健包裝市場適度細分。少數主要參與者目前在市場上佔據主導地位，包括 Gerresheimer AG、Corning Incorporated、Nipro Corporation、West Pharmaceutical Services 和 SGD SA，並且在市場份額方面也佔據主導地位。這些巨頭致力於壟斷市場並增加其在眾多國家的客戶群。這些公司使用戰術合資企業來增加市場份額和盈利能力。

• 2022 年 5 月 - Gerresheimer AG 與藥物開發公司 ISR 簽署了一項協議，為乾粉疫苗 COVID-19 的 III 期試驗大規模生產 IcoOne 鼻吸入器。作為製藥、生物技術、醫療保健和化妝品領域的合作夥伴，Gelesheimer 提供最廣泛的產品，包括用於藥品和化妝品的包裝解決方案和給藥系統。
• 2022 年 1 月 - 創新型注射給藥解決方案提供商 West Pharmaceutical Services, Inc. 宣布與 Corning, Inc. 建立獨家供應和技術合作夥伴關係。新的合作夥伴關係擴展了Corning的 Valor Glass 技術，為製藥行業提供先進的注射包裝和輸送系統，有望提高患者的安全性並增加獲得挽救生命的治療的機會。

其他好處

• Excel 格式的市場預測 (ME) 表
• 3 個月的分析師支持

內容

第一章介紹

• 研究假設和市場定義
• 調查範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場洞察

• 市場概覽
• 評估 COVID-19 對市場的影響
• 產業吸引力五力分析分析
  • 供應商的議價能力
  • 消費者的議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的敵對關係
• 工業價值鏈分析

第五章市場動態

• 市場驅動力
  • 環境問題的便利性和重要性日益增加
  • 藥品假冒的興起導致先進的包裝和標籤
• 市場挑戰
  • 與包裝原材料相關的環境問題和價格競爭

第 6 章市場細分

• 按最終用戶行業
  • 藥品
  • 醫療設備
• 按產品類型
  • 瓶/容器
  • 小瓶和安瓿
  • 墨盒/注射器
  • 小袋/包
  • 吸塑包裝
  • 管
  • 紙板箱
  • 封蓋
  • 標籤
  • 其他產品類型
• 按材料
  • 玻璃
  • 塑料
  • 其他材料（紙、金屬）
• 按地區列出
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 其他亞太地區
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲地區
  • 中東和非洲
    • 南非
    • 海灣合作委員會 (GCC)
    • 其他中東

第 7 章競爭格局

• 公司簡介
  • Gerresheimer AG
  • Corning Incorporated
  • Nipro Corporation
  • SGD SA
  • Stolze-Oberglas GmbH
  • Bormioli Pharma SRL
  • Schott AG
  • Shandong Medicinal Glass Co. Ltd
  • Beatson Clark PLC
  • Arab Pharmaceutical Glass Co
  • Piramal Glass Pvt Ltd
  • Sisecam Group

第八章投資分析

第 9 章調查市場展望

The Healthcare Packaging Market is expected to grow at a CAGR of 6.4% during the forecast period (2022 to 2027). Moreover, the healthcare industry has grown from its traditional form of practice to its current advanced position, where high-tech equipment and instruments are deployed to improve efficiency and increase demand for sustainable packaging and processing operations.

Key Highlights

• The rising awareness of environmental issues and government regulations are pushing pharmaceutical organizations to move toward sustainable processes. Also, developments by medical device and pharmaceutical vendors provide scope for expanding the healthcare packaging market globally.
• The packaging of medical devices should provide a sterile environment for their contents and remain sterile until the packaging is opened for use. The healthcare industry is growing with an increasing number of hospitals, treatment devices, and diagnostic centers. Sales of aseptic packaging are expected to increase due to growing environmental concerns and rising demand for microbial packaging.
• Healthcare companies are investing in advanced machines to increase packaging speed and efficiency. For instance, digital technology, IoT, and the blockchain allow enterprises to connect appliances to smart devices, troubleshoot and report errors, optimize operations, gain insights into machine-wide data, and record data across the supply chain.
• According to Amcor PLC in May 2022, the need for sustainable packaging includes regulatory pressure on pharmaceutical packaging companies. Pharmaceutical packaging is increasing within the scope of sustainability-oriented legislation. If the package is considered non-recyclable, the company could be subjected to the proposed Extended Producer Responsibility (EPR) taxes and penalties. Several types of pharmaceutical packaging are not recyclable and can be affected by this law.
• Further, as of May 2022, According to Food & Drug Administration, Title II of DQSA, the Drug Supply Chain Security Act (DSCSA), outlines steps to accomplish interoperable, electronic tracing of products at the package level to identify and trace certain prescription drugs as they are distributed in the United States. This will enhance FDA's capability to help safeguard consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful. These needs will also improve the detection and removal of potentially harmful drugs from the drug supply chain to protect U.S. consumers and drive companies to develop sustainable packaging solutions.
• The pharmaceutical packaging industry also faces many challenges due to the delicate nature of its products. Inadequate packaging can cause chemical changes in the development, affecting its healing ability and ineffective performance. Some challenges include supply chain disruptions, regulatory concerns, and counterfeit products.
• Moreover, the spread of COVID-19 has negatively impacted the market to a certain extent due to disruptions in the supply chain due to extended factory closures globally. Logistically, it has been difficult for bottles, vials, and ampoules makers to provide to the pharma companies. Such instances restrain the growth of the market.

Key Market Trends

Blister Packs are Expected to Witness Significant Growth

• Blister packs are one of the popular and convenient dosage formats. Companies operating in the healthcare packaging industry are economical alternatives to those offered in traditional markets where healthcare and pharmaceutical companies meet sustainability goals and shelf life requirements. Blister packs are used in medical devices and instruments such as catheters and subcutaneous syringes. However, blister packs are less useful in packaging medical devices than in pharmaceutical packaging.
• The occurrence of new diseases focused on population health management, the emergence of informed customers, and the growth of OTC (over-the-counter) drugs have augmented the growth of blister packaging in the pharmaceutical industry. Also, blister packaging has gained popularity to protect medication from moisture. In response to these trends, companies like Burgopak and Ecobliss have developed innovative blister packaging that is child-proof.
• Market vendors are making significant first-mover initiatives catering to material use. For instance, in October 2021, Astellas started employing plant-derived biomass-based polymers in blister packages as the primary packaging for pharmaceutical items. The blister package contains 50% biomass-based plastic polyethylene generated from sugarcane. It's a green packaging that adheres to the notion of carbon neutrality, which seeks to balance greenhouse gas emissions and absorption.
• Further, in April 2021, Amcor announced custom trails for the first recyclable polyethylene-based thermoform blister packaging. The new packaging is expected to launch in the market in the second half of 2022, which is designed to meet the strict standards of highly specialized and regulated pharmaceutical packaging while also providing a more sustainable alternative to the in-demand healthcare packaging type. Compared to other packaging options, the packaging has a carbon footprint of up to 70%.
• Moreover, as the healthcare, nutritional, and pharmaceutical industries are becoming mindful of the need to reduce the use of plastics that may take many years to degrade, there is an increased pressure on vendors to bring out plastic-free blister packs that may provide the same quality and maintain the shelf life of the pills. Many of the benefits inherent in the blister pack design align with the pharmaceutical industry's current demands. As a result, blister packs have been and may continue to be one of the fastest-growing packaging options in the industry.

North America is Expected to Dominate the Market

• In North America, the United States and Canada are countries with booming economies, aging population segments, well-developed health care delivery systems, gross domestic product (GDP) levels, and health insurance. However, the United States is one of the largest geographic markets for healthcare packaged products due to its advanced primary care community, extensive healthcare and life sciences research activities, high healthcare cost concentration, and large pharmaceuticals.
• According to a survey conducted by IQVIA Inc. in May 2021, total net health care costs are expected to rise from USD 359 billion in 2020 to USD 380 billion to USD 400 billion in 2025, with annual compound interest growth of 0% to 3% in the United States. New brand launches are anticipated to continue at record levels, with 50-55 new active ingredients expected to be launched each year, about USD 133 billion to be spent by 2025, slightly higher than in the last five years.
• Also, as the United States faces high drug imports from countries other than Canada, the U.S. government has approved a pilot project for wholesalers and pharmacists to import FDA-approved drug versions from Canada. The FDA implements a legal route to import certain prescription drugs from Canada to reduce the cost of certain prescription drugs to U.S. consumers without introducing additional risks to public health and safety. This leverages the healthcare packaging market with more imports into the country.
• Companies are also focused on the expansions of their business to gain more revenue in the market and sustain the competition. For instance, in June 2022, focusing on sterile barrier packages for the orthopedic medical device market, Guardian Medical USA recently raised more than USD 2.0 million in private funding. With this funding, the company will accelerate product development and facility growth to meet the growing demand and interest in using rigid tubes for sterile packaging orthopedic implants and devices of all types and sizes.
• Similarly, in September 2021, Jones Healthcare Group and Good Natured Products Inc partnered to expand sustainable packaging solutions at a new and innovative facility. With this new plant-based solution, Jones will streamline packaging design, eliminate concerns about chemicals, and make packaging easier to recycle in most homes in North America. Materials for this new custom blister pack are available from independent national chain pharmacies throughout Canada.

Competitive Landscape

The healthcare packaging market is moderately fragmented. Currently, a small number of significant players dominate the market in terms of market share, including Gerresheimer AG, Corning Incorporated, Nipro Corporation, West Pharmaceutical Services, SGD SA, and others. These major players dominate the market and concentrate on growing their clientele across numerous nations. These businesses use tactical joint ventures to raise their market shares and profitability.

• May 2022 - Gerresheimer AG has signed a contract with ISR, a drug development company, for the large-scale production of the nasal inhaler IcoOne for Phase III trials of the dry powder COVID-19 vaccine. Gerresheimer is a partner in pharmaceuticals, biotechnology, healthcare, and cosmetics, offering a very wide range of products for pharmaceutical and cosmetic packaging solutions and drug delivery systems.
• January 2022 - West Pharmaceutical Services, Inc., a provider of innovative injectable drug delivery solutions, has announced an exclusive supply and technical agreement with Corning Incorporated. The new collaboration extends Corning's Valor Glass technology, which enables advanced injectable packaging and delivery systems for the pharmaceutical industry to improve patient safety and increase access to life-saving therapies.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHT

• 4.1 Market Overview
• 4.2 Assessment of the Impact of COVID-19 on the Market
• 4.3 Industry Attractiveness Porter's Five Forces Analysis
  • 4.3.1 Bargaining Power of Suppliers
  • 4.3.2 Bargaining Power of Consumers
  • 4.3.3 Threat of New Entrants
  • 4.3.4 Threat of Substitute Products
  • 4.3.5 Intensity of Competitive Rivalry
• 4.4 Industry Value Chain Analysis

5 MARKET DYNAMICS

• 5.1 Market Drivers
  • 5.1.1 Increased Emphasis on Convenience and Environmental Issues
  • 5.1.2 Rise In Medicine Counterfeiting Leading to Advanced Packaging and Labeling
• 5.2 Market Challenges
  • 5.2.1 Environmental Concerns Related to Raw Materials for Packaging and Price Competition

6 MARKET SEGMENTATION

• 6.1 By End-User Vertical
  • 6.1.1 Pharmaceutical
  • 6.1.2 Medical Devices
• 6.2 By Product Type
  • 6.2.1 Bottles and Containers
  • 6.2.2 Vials and Ampoules
  • 6.2.3 Cartridges and Syringes
  • 6.2.4 Pouches and Bags
  • 6.2.5 Blister Packs
  • 6.2.6 Tubes
  • 6.2.7 Paper Board Boxes
  • 6.2.8 Caps and Closures
  • 6.2.9 Labels
  • 6.2.10 Other Product Types
• 6.3 By Material
  • 6.3.1 Glass
  • 6.3.2 Plastic
  • 6.3.3 Other Materials (Paper and Metal)
• 6.4 By Geography
  • 6.4.1 North America
    • 6.4.1.1 United States
    • 6.4.1.2 Canada
  • 6.4.2 Europe
    • 6.4.2.1 United Kingdom
    • 6.4.2.2 Germany
    • 6.4.2.3 Spain
    • 6.4.2.4 Italy
    • 6.4.2.5 Rest of Europe
  • 6.4.3 Asia Pacific
    • 6.4.3.1 China
    • 6.4.3.2 Japan
    • 6.4.3.3 India
    • 6.4.3.4 Australia
    • 6.4.3.5 Rest of Asia Pacific
  • 6.4.4 Latin America
    • 6.4.4.1 Mexico
    • 6.4.4.2 Brazil
    • 6.4.4.3 Rest of Latin America
  • 6.4.5 Middle East and Africa
    • 6.4.5.1 South Africa
    • 6.4.5.2 Gulf Cooperation Council (GCC)
    • 6.4.5.3 Rest of Middle East and Africa

7 COMPETITIVE LANDSCAPE

• 7.1 Company Profiles
  • 7.1.1 Gerresheimer AG
  • 7.1.2 Corning Incorporated
  • 7.1.3 Nipro Corporation
  • 7.1.4 SGD SA
  • 7.1.5 Stolze-Oberglas GmbH
  • 7.1.6 Bormioli Pharma SRL
  • 7.1.7 Schott AG
  • 7.1.8 Shandong Medicinal Glass Co. Ltd
  • 7.1.9 Beatson Clark PLC
  • 7.1.10 Arab Pharmaceutical Glass Co
  • 7.1.11 Piramal Glass Pvt Ltd
  • 7.1.12 Sisecam Group

8 INVESTMENT ANALYSIS

9 OUTLOOK OF THE MARKET STUDIED